Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Current Liabilities (2016 - 2025)

Corcept Therapeutics' Total Current Liabilities history spans 10 years, with the latest figure at $166.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 17.98% year-over-year to $166.1 million; the TTM value through Dec 2025 reached $166.1 million, up 17.98%, while the annual FY2025 figure was $166.1 million, 17.98% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $166.1 million at Corcept Therapeutics, down from $172.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $172.3 million in Q3 2025 and bottomed at $40.6 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $99.0 million (2024), against an average of $101.7 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 89.7% in 2023 before it rose 8.26% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $40.6 million in 2021, then surged by 78.54% to $72.5 million in 2022, then skyrocketed by 44.16% to $104.5 million in 2023, then surged by 34.7% to $140.8 million in 2024, then rose by 17.98% to $166.1 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Total Current Liabilities are $166.1 million (Q4 2025), $172.3 million (Q3 2025), and $140.8 million (Q4 2024).